Author: Editor

Myeloma expert Dr. Robert Orlowski answers more Ask the Expert questions, this one from Susan: What effect will newly approved drugs, such as daratumamab and ixazomib have on a patient when Revlimid maintenance is no longer effective? Dr. Orlowski gives a detailed answer, including a newer drug, isatuximab, that he says, looks like an active and exciting drug. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At a recent MPN town meeting, MPN experts Dr. Srdan Verstovsek and Dr. Naval Daver from MD Anderson Cancer Center and Dr. Rami Komrokji from Moffitt Cancer discussed treatment considerations for myelofibrosis patients prior to stem cell transplant. Each of the experts shares their perspective on how genetic testing shapes treatment choices, how age affects the decision, and why or why not a particular patient makes a good candidate for transplant. Watch to learn more about why this is an individualized decision for each patient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info…

Watch an in-depth discussion on emerging immunotherapy approaches for advanced prostate cancer with MD Anderson Cancer Center experts, Drs. Sumit Subudhi and Jeri Kim. Learn about treatments including experimental vaccine treatments and checkpoint inhibitors/immune modulators. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark provides an overview of the LUMIERE clinical trial of alisertib (MLN8237), an Aurora A kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. When compared to standard of care, such as romidepsin, pralatrexate and gemcitabine, there was no difference in terms of efficacy. However, Dr D’Amore discusses that this clinical was a great achievement in a field of rare diseases such as T-cell lymphomas.

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of a bromodomain and extra-terminal motif (BET) inhibitor for the treatment of non-Hodgkin lymphoma in a first in-human Phase I study.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib.

Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 965 of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of the multi-centre prospective Phase II study of Dose-Adjusted EPOCH-R for Burkitt Lymphoma.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, discusses topics of his highlight session at the congress that summarised research highlights in the management of patients with ovarian cancer in 2015, including the treatment of relapsed ovarian cancer and optimisation of the use of poly(ADP-ribose) polymerase (PARP) inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD, from National Cancer Center, Kashiwa, Japan, reviews promising approaches for the treatment of patients with gastrointestinal cancer, including molecular targeted therapies and clinical studies of anti-PD-1 antibodies, such as pembrolizumab, for advanced gastric or gastroesophageal junction adenocarcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD, PhD, from the University of Valencia, Valencia, Spain, explains the approach to case study sessions at the congress, which are guided by expert-reviewed and evidence-based ESMO guidelines and aim to promote the international exchange of expertise between Asian and European oncologists. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the clinical development of immune checkpoint inhibitors, including pembrolizumab, an anti-PD-1 antibody, and durvalumab, an anti-PD-L1 antibody, for the treatment of patients with head and neck cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses subgroup analyses and patient-reported outcomes from CheckMate 057, a phase 3, randomised clinical trial that was designed to compare nivolumab, an antiPD-1 antibody, with docetaxel for the treatment of patients with advanced non-squamous non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses a phase 1b clinical trial that was designed to evaluate the safety and antitumour activity of durvalumab, an anti-PD-L1 antibody, combined with tremelimumab, a CTLA-4 antibody, for the treatment of patients with stage III or IV non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the subgroup and biomarker analysis of LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from Champalimaud Cancer Centre, Lisbon, Portugal, discusses the implementation of ESMO guidelines on the treatment of metastatic HER2-positive breast cancer in a case study presentation, including the use of the antibody-drug conjugate, T-DM1, and the anti-HER2 antibody, pertuzumab, in different settings of treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD, from the Melanoma Institute Australia, Sydney, Australia, discusses the opportunities and challenges of promising immunotherapeutic approaches for the treatment of patients with melanoma, including immune checkpoint inhibitors that target pathways related to T-cell activity. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ, provides an overview of the session “Social Media for the Hematologist” held at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. In this session, it was discussed how social media has become a part of medical practice, research, education, and the value of these tools and how to use them effectively.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, explains that the ESMO Asia Congress provides an opportunity for Asian and European oncologists to come together to promote an exchange of expertise, and highlights the access of new medicines as a global challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, provides an overview of approaches that aim to improve patient access to new cancer medicines, including the ESMO Magnitude of Clinical Benefit Scale, which is a validated approach to stratify the magnitude of clinical benefit for cancer medicines. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses an evaluation of overall health status in patients with advanced squamous non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 antibody, or docetaxel in CheckMate 017; and subgroup analyses and patient reported outcomes in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, discusses the therapeutic development and impact of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, for the management of patients with BRCA-related ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, explains that recent developments in the treatment of castrate-resistant prostate cancer have improved overall survival for patients, and now, optimal sequencing of new treatment agents and approaches, such as abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T, is the next challenge. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Richard A. Van Etten, MD of UC Irvine Health Chao Family gives an update on Chronic Myeloid Leukemia using data from ASH at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Susan OBrien, MD of UC Irvine Health Chao Family gives an update of Chronic Lymphocytic Leukemia with data from ASH 2015 at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Kanwarpal S. Kahlon , MD of UC Irvine Health Chao Family gives an Update on Multiple Myeloma at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Deepa Jeyakumar, MD of UC Irvine Health Chao Family gives an update on Acute Myeloid Leukemia at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Angela Fleischman, MD, PhD of University of California, Irvine discusses Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials; Anti-Fibrotic Agents at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Monica El-Masry, MD & Bhavana Pathak, MD present Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach

Eric Van Cutsem, MD of University of Leuven discusses the RECOURSE trial design and its primary endpoint results at ASCO Gi 2016

Eric Van Cutsem, MD of University of Leuven discusses the risk-benefit ratio for TAS-102 in advanced treatment refractory colorectal cancer at ASCO GI 2016

Eric Van Cutsem, MD of University of Leuven discusses a subgroup analysis of the RECOURSE trial and new information regarding TAS-102 and its effects at ASCO GI 2016         clinical trial, received tas-102, tas-102

Eric Van Cutsem, MD of University of Leuven discusses the TAS-102 mechanism of action and potential toxicity in advanced CRC

Eric Van Cutsem, MD of University of Leuven discusses the therapeutic algorithm for TAS-102 in metastatic colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the design of the RECOURSE trial on which the FDA approved TAS-102 at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the performance status of patients in the RECOURSE trial at ASCCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal cancer

Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses key trials that will move treatment forward in colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses why more money should be allocated to early detection and screening in colorectal cancer at ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses potential cases to use Regorafenib over TAS-102 ASCO GI 2016

Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016

Alan P. Venook, MD of University of California San Francisco discusses using TAS-102 after initial therapy with regorafenib at ASCO Gi 2016

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of isatuximab (SAR650984) for the treatment of relapsed/refractory multiple myeloma (MM). Isatuximab is an anti-CD38 monoclonal antibody, that is very well tolerated by MM patients, with a response rate of 20-29% based on different cohorts. This drug is now being taken into a larger Phase II trial with over 100 patients taking one single dose of isatuximab. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL. To see more videos go to http://www.vjhemonc.com/ Facebook: https://www.facebook.com/vjhemonc…

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, explains that oncologists and other clinical staff, who possess highly technical expertise in the management of cancer, can have an important role in providing genetic counselling for patients diagnosed with ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Maria-Victoria Mateos, MD, PhD from the University Hospital of Salamaca, Spain provides an overview of the SIRIUS clinical trial of daratumumab, an anti-CD38 monoclonal antibody, in the treatment of relapsed/refractory multiple myeloma (MM) patients. Approximately 100 patients received daratumumab as a single-agent, and 30% of these responded to daratumumab. Dr Mateos discusses the importance of these results, as currently treatment for this patient population is an unmet need. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.